1st June 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Sugammadex anaesthesia drugs launched in India by BDR Pharma and Varenyam

Sugmadex, a first-of-its-kind drug with novel cyclodextrin neuromuscular block reversal properties and resulting in the removal of anaesthesia effect on the body, has been launched in India by Mumbai-based BDR Pharmaceuticals and Varenyam Healthcare.

ENTOD Pharma's Phase III study of 0.05 percent Atropine eye drops approved by DCGI

ENTOD Pharmaceuticals announced that it has received approval from the Drug Controller General of India to conduct phase 3 trials across the country for its 0.05 percent atropine eye drops, which are used to treat eye problems

Affinivax, a clinical-stage biopharmaceutical company acquired by GSK

After announcing a $3.3 billion deal to buy pneumonia vaccine maker Affinivax on Tuesday, GlaxoSmithKline (GSK) is squaring off with Pfizer (PFE) and Merck (MRK).

Sandoz launched a new global initiative entitled 'Act4Biosimilars'

Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of ‘Act4Biosimilars, ‘ a new global initiative aimed at addressing health inequity and inequality around the world.

USFDA approved Abbott's FreeStyle Libre 3

FDA has cleared Abbott’s next-generation FreeStyle Libre 3 system for use by diabetics aged four and up6. With readings sent directly to smartphone every minute, FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor available.

Kymriah bags from Novartis Yescarta received FDA approval

Despite a high-profile trial failure, Novartis is sticking with its CAR-T therapy Kymriah. The drug recently received FDA approval, allowing it to compete in the most common indolent lymphoma with Gilead Sciences’ competitor, Yescarta.

Fylnetra, a Neulasta biosimilar approved by the FDA

Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, has been approved by the Food and Drug Administration (FDA). Fylnetra is expected to be available in the second half of 2022, according to Amneal Pharmaceuticals.